55.42
+1.11(+2.04%)
Currency In USD
| Previous Close | 54.31 |
| Open | 53.99 |
| Day High | 56.07 |
| Day Low | 53.45 |
| 52-Week High | 57.99 |
| 52-Week Low | 24.1 |
| Volume | 743,362 |
| Average Volume | 1.41M |
| Market Cap | 5.26B |
| PE | -12.23 |
| EPS | -4.53 |
| Moving Average 50 Days | 46.41 |
| Moving Average 200 Days | 36.44 |
| Change | 1.11 |
If you invested $1000 in Crinetics Pharmaceuticals, Inc. (CRNX) since IPO date, it would be worth $2,261.12 as of January 14, 2026 at a share price of $55.42. Whereas If you bought $1000 worth of Crinetics Pharmaceuticals, Inc. (CRNX) shares 5 years ago, it would be worth $3,749.66 as of January 14, 2026 at a share price of $55.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jan 12, 2026 9:05 PM GMT
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggr
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire Inc.
Jan 07, 2026 2:22 AM GMT
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocri
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
GlobeNewswire Inc.
Jan 05, 2026 1:00 PM GMT
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) Achieved a 67% Mean Reduction in Androstened